Fineline Cube

Follow:
14486 Articles
Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA
CompanyDrug

Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease
CompanyDrug

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease

XtalPi and Bio‑Sincerity Announce AI‑Robotics R&D Partnership
CompanyDeals

XtalPi and Bio‑Sincerity Announce AI‑Robotics R&D Partnership

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration
Others

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration

Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL
CompanyDrug

Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera
Drug

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy
Medical Device

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317
Drug

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
CompanyMedical Device

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer
CompanyDeals

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
CompanyDrug

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist